CD274 and neoplasm: For this, mice bearing NB9464 tumors were randomized in four different groups when tumors reached 100 mm3 and were treated with either vehicle (IgG antibody), or 100 μg anti-PDL1 mAb or 25 mg/kg ibrutinib or the combination of ibrutinib and anti-PDL1mAb as shown in Figure 6A. The combination of ibrutinib and anti-PDL1 mAb significantly reduced tumor growth as compared to the use of a single agent (Figure 6B).